Yifan Pharmaceutical (002019): Proprietary formulations and innovative drugs have entered the release cycle, and the trend of reversal in performance is clear
Yifan Pharmaceutical (002019): The risk of impairment has been cleared, and the inflection point of significant growth of its own products has arrived
Yifan Pharmaceutical (002019): 2023 results are in line with expectations, and both revenue and profit growth accelerated in 2024Q1
Yifan Pharmaceutical (002019) Quarterly Report Review: The inflection point of performance has reached a rapid growth rate that exceeds market expectations and the growth of the main pharmaceutical industry is driving volume
Pacific released a research report on April 25 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating, and the target price was 18.80 yuan. The main reasons for the rating include: 1) Q1 performance exceeded expectations and formulation
Yifan Pharmaceutical (002019): Q1 performance exceeds expectations, lightweight and looks forward to high growth
Pacific released a research report on April 22 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating. The main reasons for the rating include: 1) the main business is growing steadily, and the share of pharmaceutical-owned products con
Yifan Pharmaceutical (002019): After deducting impairment, it is lightweight and optimistic about the global release of innovative products
Yifan Pharmaceutical (002019) Annual Report Review Report: The growth rate of pharmaceutical products is relatively rapid, and the innovation pipeline is gradually entering a harvest period, and performance will reach an inflection point
Pacific released a research report on April 11 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating, and the target price was 18.00 yuan. The main reasons for the rating include: 1) the company's product business structure has been op
Yifan Pharmaceutical (002019): Business structure transformation and upgrading to achieve a new journey of innovation and internationalization
Yifan Pharmaceutical (002019): Impairment, implementation, and lightweight, 24 years of innovation, transformation, and gradual fulfillment of expectations ushered in an inflection point in performance
Yifan Pharmaceutical (002019): Depreciation implemented, lightweight innovation pipeline entered the harvest period
Yifan Pharmaceutical (002019) Company Brief Review Report: Innovative Drugs Entering the Cash Period, Performance Reversal Is Imminent
Yifan Pharmaceutical (002019): The bottom of the performance was reversed, and various drugs achieved phased results
Yifan Pharmaceutical (002019) Company Review: The F-652ACLFII phase results are positive, and it is expected that production will be reported in 2-3 years to meet unfinished clinical needs
Yifan Pharmaceutical (002019): The clinical value of the phase III study with a peak of 5 billion ebergistine published and re-emphasized
Yifan Pharmaceutical (002019): Innovative Drugs Successfully Gone Overseas, Own Formulation Business Enters Harvest Period
Yifan Pharmaceuticals (002019): One drum of energy finally dawns, going overseas and setting sail around the world
Yifan Pharmaceutical (002019): Sales of self-developed products have entered the harvest period and deepened in overseas markets
No Data